Navigation Links
Stereotaxis Appoints Senior Vice President, North America
Date:6/20/2008

Responsible for Sales and Clinical Services

ST. LOUIS, June 20 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it has enhanced its senior management team for North American sales and clinical services with the appointment of Louis Ruggiero as Senior Vice President, North America. Mr. Ruggiero was most recently Chief Sales & Marketing Officer at DJ Orthopedics, formerly was President and CEO of Titan Scan Technologies Corporation, and is a 10-year veteran at General Electric Medical Systems. Mr. Ruggiero will report to Michael P. Kaminski, President and Chief Operating Officer of Stereotaxis.

"Lou brings to Stereotaxis 25 years of progressive sales, marketing and general management experience in the healthcare industry," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "His background includes sales leadership positions at both emerging and well-established medical device companies. We anticipate that Lou will play a key role, strengthening our sales effort and driving operational efficiencies. He has a track record for generating strong revenue growth and driving profits, and we believe that Lou will quickly become an important asset to our company."

Mr. Ruggiero, 48, joins Stereotaxis from DJ Orthopedics (DJO), where he served as Chief Sales and Marketing Officer and Corporate Officer from 2003 until the Company was acquired by The Blackstone Group in 2007. During his four-year tenure at DJO, Mr. Ruggiero helped the Company double sales growth to $375 million. Prior to joining DJO, Mr. Ruggiero spent four years at Titan Scan Technologies Corporation as President and Chief Executive Officer. In that time he led Titan to more than $50 million in sales, from $7 million.

Mr. Ruggiero earned his M.B.A. in General Management and Marketing at the J.L. Kellogg Graduate School of Management at Northwestern University, and his B.A. in Political Science and Interpersonal Communication at
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
7. Stereotaxis to Present at the Seventh Annual JMP Securities Research Conference
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... a deicing film for radar domes have now refined ... glass. , The new work by Rice chemist ... from windshields to skyscrapers free of ice and fog ... , The technology was introduced this month in the ... . , The material is made of graphene ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... -- As open enrollment season approaches, U.S. employees will soon ... benefits. According to Aon Hewitt , the global ... plc (NYSE: AON ), employees will ... managing their health care decisions. This increased responsibility makes ... how they can make the most of the programs ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... "crack baby" hysteria of the 1980s was greatly ... but disabling cognitive impairments -- attention deficits, learning ... study by investigators at the Vanderbilt Kennedy Center ... the long-term behavioral and neurological problems associated with ...
... especially those that are hydrophobic or water-repellant, to tumors ... develop innovative delivery systems that keep these drugs intact ... University at Buffalo’s Institute for Lasers, Photonics and Biophotonics ... solution in which the delivery system is the drug ...
... Researchers have linked a structural protein called nestin to ... new biomarker that could lead to earlier detection and ... of Cancer Research, researchers from Dartmouth Medical School demonstrate ... basal epithelial breast tumors, a highly aggressive cancer with ...
Cached Biology News:Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3No carrier necessary: This drug delivers itself 2Selective marker found to indicate aggressive form of breast cancer 2
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: